Cited 0 time in
Lipid-based polymeric biomaterial-mediated ex vivo natural killer cell surface engineering
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Park, Jaewon | - |
| dc.contributor.author | Noh, Kyung Mu | - |
| dc.contributor.author | Kim, Kyobum | - |
| dc.date.accessioned | 2025-07-22T01:00:11Z | - |
| dc.date.available | 2025-07-22T01:00:11Z | - |
| dc.date.issued | 2025-08 | - |
| dc.identifier.issn | 2047-4830 | - |
| dc.identifier.issn | 2047-4849 | - |
| dc.identifier.uri | https://scholarworks.dongguk.edu/handle/sw.dongguk/58761 | - |
| dc.description.abstract | Natural killer (NK) cell-based immunotherapy has gained significant attention due to its ability to selectively recognize and eliminate cancer cells through immunological synapse formation while sparing normal cells. However, the therapeutic efficacy of NK cells against solid tumors remains limited, primarily due to insufficient tumor-specific targeting ligands. Although chimeric antigen receptor (CAR)-engineered NK cell therapy has been developed to address this challenge, its clinical translation is hindered by challenges like high cost, low transfection efficiency, and concerns associated with genetic modification. As an alternative, biomaterial-based NK cell surface engineering has emerged as a promising strategy to enhance tumor-targeting capabilities, without altering the intrinsic properties of NK cells. In particular, lipid-based polymeric biomaterial platforms enable efficient ligand-receptor interactions, thereby enhancing NK cell-mediated tumor recognition and cytotoxicity. This review highlights recent advances in the lipid-based NK cell surface engineering platform, discussing its advantages over genetic modifications and its potential to improve the efficacy of NK cell-based cancer immunotherapy. | - |
| dc.format.extent | 21 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | Royal Society of Chemistry | - |
| dc.title | Lipid-based polymeric biomaterial-mediated ex vivo natural killer cell surface engineering | - |
| dc.type | Article | - |
| dc.publisher.location | 영국 | - |
| dc.identifier.doi | 10.1039/d5bm00692a | - |
| dc.identifier.scopusid | 2-s2.0-105010609740 | - |
| dc.identifier.wosid | 001528677700001 | - |
| dc.identifier.bibliographicCitation | Biomaterials Science, v.13, no.17, pp 4576 - 4596 | - |
| dc.citation.title | Biomaterials Science | - |
| dc.citation.volume | 13 | - |
| dc.citation.number | 17 | - |
| dc.citation.startPage | 4576 | - |
| dc.citation.endPage | 4596 | - |
| dc.type.docType | Review | - |
| dc.description.isOpenAccess | Y | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Materials Science | - |
| dc.relation.journalWebOfScienceCategory | Materials Science, Biomaterials | - |
| dc.subject.keywordPlus | CAR-NK CELLS | - |
| dc.subject.keywordPlus | STEM-CELLS | - |
| dc.subject.keywordPlus | T-CELLS | - |
| dc.subject.keywordPlus | CANCER | - |
| dc.subject.keywordPlus | IMMUNOTHERAPY | - |
| dc.subject.keywordPlus | NANOENCAPSULATION | - |
| dc.subject.keywordPlus | DELIVERY | - |
| dc.subject.keywordAuthor | Lipid | - |
| dc.subject.keywordAuthor | Antigens | - |
| dc.subject.keywordAuthor | Biomaterials | - |
| dc.subject.keywordAuthor | Cell Engineering | - |
| dc.subject.keywordAuthor | Cell Membranes | - |
| dc.subject.keywordAuthor | Cytology | - |
| dc.subject.keywordAuthor | Diseases | - |
| dc.subject.keywordAuthor | Molecular Biology | - |
| dc.subject.keywordAuthor | Cancer Cells | - |
| dc.subject.keywordAuthor | Cell Surface Engineering | - |
| dc.subject.keywordAuthor | Cell-based | - |
| dc.subject.keywordAuthor | Ex-vivo | - |
| dc.subject.keywordAuthor | Genetic Modifications | - |
| dc.subject.keywordAuthor | Immunological Synapse | - |
| dc.subject.keywordAuthor | Natural Killer Cells | - |
| dc.subject.keywordAuthor | Polymeric Biomaterials | - |
| dc.subject.keywordAuthor | Solid Tumors | - |
| dc.subject.keywordAuthor | Therapeutic Efficacy | - |
| dc.subject.keywordAuthor | Ligands | - |
| dc.subject.keywordAuthor | Tumors | - |
| dc.subject.keywordAuthor | Biomaterial | - |
| dc.subject.keywordAuthor | Chimeric Antigen Receptor | - |
| dc.subject.keywordAuthor | Lipid | - |
| dc.subject.keywordAuthor | Cancer Immunotherapy | - |
| dc.subject.keywordAuthor | Cell Surface | - |
| dc.subject.keywordAuthor | Cellular Immunotherapy | - |
| dc.subject.keywordAuthor | Chimeric Antigen Receptor Natural Killer Cell Immunotherapy | - |
| dc.subject.keywordAuthor | Cytotoxicity | - |
| dc.subject.keywordAuthor | Ex Vivo Study | - |
| dc.subject.keywordAuthor | Genetic Modification | - |
| dc.subject.keywordAuthor | Genetic Transfection | - |
| dc.subject.keywordAuthor | Human | - |
| dc.subject.keywordAuthor | Human Cell | - |
| dc.subject.keywordAuthor | Immunological Synapse | - |
| dc.subject.keywordAuthor | Natural Killer Cell | - |
| dc.subject.keywordAuthor | Pharmaceutics | - |
| dc.subject.keywordAuthor | Polymerization | - |
| dc.subject.keywordAuthor | Review | - |
| dc.subject.keywordAuthor | Solid Tumor | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
30, Pildong-ro 1-gil, Jung-gu, Seoul, 04620, Republic of Korea+82-2-2260-3114
Copyright(c) 2023 DONGGUK UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
